IRWD vs. ZNTL, CYRX, IGMS, KURA, BHC, FOLD, NVAX, GERN, CLDX, and MYGN
Should you be buying Ironwood Pharmaceuticals stock or one of its competitors? The main competitors of Ironwood Pharmaceuticals include Zentalis Pharmaceuticals (ZNTL), Cryoport (CYRX), IGM Biosciences (IGMS), Kura Oncology (KURA), Bausch Health Companies (BHC), Amicus Therapeutics (FOLD), Novavax (NVAX), Geron (GERN), Celldex Therapeutics (CLDX), and Myriad Genetics (MYGN).
Zentalis Pharmaceuticals (NASDAQ:ZNTL) and Ironwood Pharmaceuticals (NASDAQ:IRWD) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, earnings, community ranking, dividends, profitability, risk, valuation, media sentiment and analyst recommendations.
Zentalis Pharmaceuticals presently has a consensus price target of $31.67, suggesting a potential upside of 198.18%. Ironwood Pharmaceuticals has a consensus price target of $18.40, suggesting a potential upside of 189.76%. Given Ironwood Pharmaceuticals' higher probable upside, equities analysts clearly believe Zentalis Pharmaceuticals is more favorable than Ironwood Pharmaceuticals.
Ironwood Pharmaceuticals received 452 more outperform votes than Zentalis Pharmaceuticals when rated by MarketBeat users. However, 65.00% of users gave Zentalis Pharmaceuticals an outperform vote while only 61.09% of users gave Ironwood Pharmaceuticals an outperform vote.
In the previous week, Ironwood Pharmaceuticals had 2 more articles in the media than Zentalis Pharmaceuticals. MarketBeat recorded 7 mentions for Ironwood Pharmaceuticals and 5 mentions for Zentalis Pharmaceuticals. Ironwood Pharmaceuticals' average media sentiment score of 0.80 beat Zentalis Pharmaceuticals' score of 0.59 indicating that Zentalis Pharmaceuticals is being referred to more favorably in the media.
Zentalis Pharmaceuticals has a beta of 1.83, indicating that its share price is 83% more volatile than the S&P 500. Comparatively, Ironwood Pharmaceuticals has a beta of 0.51, indicating that its share price is 49% less volatile than the S&P 500.
Zentalis Pharmaceuticals has a net margin of 0.00% compared to Zentalis Pharmaceuticals' net margin of -254.41%. Zentalis Pharmaceuticals' return on equity of -28.45% beat Ironwood Pharmaceuticals' return on equity.
Zentalis Pharmaceuticals has higher earnings, but lower revenue than Ironwood Pharmaceuticals. Zentalis Pharmaceuticals is trading at a lower price-to-earnings ratio than Ironwood Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Summary
Zentalis Pharmaceuticals and Ironwood Pharmaceuticals tied by winning 8 of the 16 factors compared between the two stocks.
Get Ironwood Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for IRWD and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding IRWD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Ironwood Pharmaceuticals Competitors List
Related Companies and Tools
